Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma

BMC Complementary and Alternative Medicine

Shun-Fa Yang⁴  Ming-Ju Hsieh¹  Hui-Ling Chiou²  Chiao-Wen Lin³  Yung-Luen Yu⁵  Chao-Bin Yeh⁶ 

[1] Institute of Medicine, Chung Shan Medical University, 110 Section 1, Chien-Kuo N. Road, South District, Taichung, Taiwan;School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan;Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan;Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan;Department of Biotechnology, Asia University, Taichung, Taiwan;Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan

关键词: u-PA;    Invasion;    Migration;    Terminalia catappa;    Hepatocellular carcinoma;   

Others  :  1220182
DOI  :  10.1186/1472-6882-14-141

 received in 2013-04-25, accepted in 2014-04-25,  发布年份 2014

【 摘 要 】

Background

The survival rate of malignant tumors, and especially hepatocellular carcinoma (HCC), has not improved primarily because of uncontrolled metastasis. In our previous studies, we have reported that Terminalia catappa leaf extract (TCE) exerts antimetastasis effects on HCC cells. However, the molecular mechanisms of urokinase-type plasminogen activator (u-PA) in HCC metastasis have not been thoroughly investigated, and remain poorly understood.

Methods

The activities and protein levels of u-PA were determined by casein zymography and western blotting. Transcriptional levels of u-PA were detected by real-time PCR and promoter assays.

Results

We found that treatment of Huh7 cells with TCE significantly reduced the activities, protein levels and mRNA levels of u-PA. A chromatin immunoprecipitation (ChIP) assay showed that TCE inhibited the transcription protein of nuclear factors SP-1 and NF-κB. TCE also did inhibit the effects of u-PA by reducing the phosphorylation of ERK1/2 pathway.

Conclusions

These results show that u-PA expression may be a potent therapeutic target in the TCE-mediated suppression of HCC metastasis.

【 授权许可】

   
2014 Yeh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Min L, He B, Hui L: Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol 2011, 21:10-20.
• [2]El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
• [3]Yeh CB, Hsieh MJ, Hsieh YS, Chien MH, Lin PY, Chiou HL, Yang SF: Terminalia catappa exerts antimetastatic effects on hepatocellular carcinoma through transcriptional inhibition of matrix metalloproteinase-9 by modulating NF-κB and AP-1 activity. Evid Based Complement Alternat Med 2012, 595292.
• [4]Yeh CB, Hsieh MJ, Lin CW, Chiou HL, Lin PY, Chen TY, Yang SF: The antimetastatic effects of resveratrol on hepatocellular carcinoma through the downregulation of a metastasis-associated protease by SP-1 modulation. PLoS One 2013, 8:e56661.
• [5]Andreasen PA, Kjøller L, Christensen L, Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997, 72:1-22.
• [6]Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34:122-136.
• [7]Stepanova VV, Tkachuk VA: Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry 2002, 67:109-118.
• [8]Kim BM, Lee DH, Choi HJ, Lee KH, Kang SJ, Joe YA, Hong YK, Hong SH: The recombinant kringle domain of urokinase plasminogen activator inhibits VEGF165-induced angiogenesis of HUVECs by suppressing VEGFR2 dimerization and subsequent signal transduction. IUBMB Life 2012, 64:259-265.
• [9]Weng CJ, Tsai CM, Chen YC, Hsieh YH, Lin CW, Liu YF, Su SC, Chen MK, Yang SF: Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010, 17:3394-3401.
• [10]Thummarati P, Wijitburaphat S, Prasopthum A, Menakongka A, Sripa B, Tohtong R, Suthiphongchai T: High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. World J Gastroenterol 2012, 18:244-250.
• [11]Tang L, Han X: The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother 2013, 67:179-182.
• [12]del Rosso M, Margheri F, Serratì S, Chillà A, Laurenzana A, Fibbi G: The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr Pharm Des 2011, 17:1924-1943.
• [13]Liotta LA, Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51:5054s-5059s.
• [14]Yang SF, Chen MK, Hsieh YS, Yang JS, Zavras AI, Hsieh YH, Su SC, Kao TY, Chen PN, Chu SC: Antimetastatic effects of Terminalia catappa L. on oral cancer via a down-regulation of metastasis-associated proteases. Food Chem Toxicol 2010, 48:1052-1058.
• [15]Tang X, Gao J, Wang Y, Fan YM, Xu LZ, Zhao XN, Xu Q, Qian ZM: Effective protection of Terminalia catappa L. leaves from damage induced by carbon tetrachloride in liver mitochondria. J Nutr Biochem 2006, 17:177-182.
• [16]Tang XH, Gao J, Dou H, Wang YP, Xu LZ, Zhu ZR, Xu Q: Protective effect of the extract of Terminalia catappa leaves on acute liver injury induced by D-GalN in mice. Zhongguo Zhong Yao Za Zhi 2004, 29:1069-1073.
• [17]Hu Q, Lu YY, Noh H, Hong S, Dong Z, Ding HF, Su SB, Huang S: Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression. Oncogene 2012, 32:3933-3943.
• [18]He X, Zheng Z, Li J, Ben Q, Liu J, Zhang J, Ji J, Yu B, Chen X, Su L, Zhou L, Liu B, Yuan Y: DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating RC/ERK/uPA. Carcinogenesis 2012, 33:555-562.
• [19]Malinowsky K, Wolff C, Berg D, Schuster T, Walch A, Bronger H, Mannsperger H, Schmidt C, Korf U, Höfler H, Becker KF: uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases. Transl Oncol 2012, 5:98-104.
• [20]Itoh T, Hayashi Y, Kanamaru T, Morita Y, Suzuki S, Wang W, Zhou L, Rui JA, Yamamoto M, Kuroda Y, Itoh H: Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J Gastroenterol Hepatol 2000, 15:422-430.
• [21]Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000, 126:641-646.
• [22]von der Ahe D, Pearson D, Nakagawa J, Rajput B, Nagamine Y: Multiple nuclear factors interact with promoter sequences of the urokinase-type plasminogen activator gene. Nucleic Acids Res 1998, 16:7527-7544.
• [23]Tavian D, Salvi A, de Petro G, Barlati S: Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells. Cancer Gene Ther 2003, 10:112-120.
• [24]Salvi A, Arici B, de Petro G, Barlati S: Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004, 3:671-678.
• [25]Salvi A, Arici B, Alghisi A, Barlati S, de Petro G: RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice. Tumour Biol 2007, 28:16-26.
• [26]Chu SC, Yang SF, Liu SJ, Kuo WH, Chang YZ, Hsieh YS: In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells. Food Chem Toxicol 2007, 45:1194-1201.
• [27]Yang SF, Yang WE, Kuo WH, Chang HR, Chu SC, Hsieh YS: Antimetastatic potentials of flavones on oral cancer cell via an inhibition of matrix-degrading proteases. Arch Oral Biol 2008, 53:287-294.
• [28]Yang SF, Chu SC, Liu SJ, Chen YC, Chang YZ, Hsieh YS: Antimetastatic activities of Selaginella tamariscina (Beauv.) on lung cancer cells in vitro and in vivo. J Ethnopharmacol 2007, 110:483-489.
• [29]Yang SF, Chen MK, Hsieh YS, Chung TT, Hsieh YH, Lin CW, Su JL, Tsai MH, Tang CH: Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem 2010, 285:29808-29816.
• [30]Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 1976, 72:248-254.
• [31]Takada Y, Singh S, Aggarwal BB: Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 2004, 279:15096-15104.
• [32]Lee KH, Hyun MS, Kim JR: Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Metastasis 2003, 20:499-505.
• [33]Price JT, Bonovich MT, Kohn EC: The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 1997, 23:175-253.
• [34]Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG: Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 1997, 11:229-244.
• [35]Yeh CB, Hsieh MJ, Hsieh YH, Chien MH, Chiou HL, Yang SF: Antimetastatic effects of norcantharidin on hepatocellular carcinoma by transcriptional inhibition of MMP-9 through modulation of NF-kB activity. PLoS One 2012, 7:e31055.
• [36]Kinoshita S, Inoue Y, Nakama S, Ichiba T, Aniya Y: Antioxidant and hepatoprotective actions of medicinal herb, Terminalia catappa L. from Okinawa Island and its tannin corilagin. Phytomedicine 2007, 14:755-762.
• [37]Lin CC, Chen YL, Lin JM, Ujiie T: Evaluation of the antioxidant and hepatoprotective activity of Terminalia catappa. Am J Chin Med 1997, 25:153-161.
• [38]Liu TY, Ho LK, Tsai YC, Chiang SH, Chao TW, Li JH, Chi CW: Modification of mitomycin C-induced clastogenicity by Terminalia catappa L. in vitro and in vivo. Cancer Lett 1996, 105:113-118.
• [39]Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways. Endocr Rev 2001, 22:153-183.
• [40]Reddy KB, Nabha SM, Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 2003, 22:395-403.
• [41]Lee HC, Tian B, Sedivy JM, Wands JR, Kim M: Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006, 131:1208-1217.
• [42]Sugioka Y, Watanabe T, Inagaki Y, Kushida M, Niioka M, Endo H, Higashiyama R, Okazaki I: c-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line. Int J Cancer 2004, 109:867-874.
• [43]Reunanen N, Westermarck J, Hakkinen L, Holmstrom TH, Elo I, Eriksson JE, Kähäri VM: Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem 1998, 273:5137-5145.
• [44]Huang WS, Chin CC, Chen CN, Kuo YH, Chen TC, Yu HR, Tung SY, Shen CH, Hsieh YY, Guo SE, Shi CS, Liu TJ, Kuo HC: Stromal cell-derived factor-1/CXC receptor 4 and β1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells. J Cell Physiol 2012, 227:1114-1122.
• [45]Ko TF, Weng YM, Lin SB, Chiou RY: Antimutagenicity of supercritical CO2 extracts of Terminalia catappa leaves and cytotoxicity of the extracts to human hepatoma cells. J Agric Food Chem 2003, 51:3564-3567.